Marshall Wace’s BridgeBio Oncology BBOT Stock Holding History

Marshall Wace’s Portfolio BBOT Stock Details BBOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.98M	Buy	+482,935	New	+$3.75M	﹤0.01%	1819

Other funds holding BBOT

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return

Regents of the University of California Oakland, California $6.64B AUM 23.46% 1-Year Est. Return

Laurion Capital Management New York $6.21B AUM 32.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Aisling Capital Management New York $299M AUM 39.78% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return

Marshall Wace's BBOT Position: Q3 2026 in Review

Marshall Wace opened a new position in BridgeBio Oncology (BBOT) in Q3 2026: 482,935 shares worth $1.98M. The stake represents ﹤0.01% of the portfolio and ranks #1819 among its holdings.

44 funds tracked by Wall St. Rank hold BBOT as of Q3 2026.

Marshall Wace held 482,935 shares of BridgeBio Oncology worth $1.98M as of Q3 2026.
BridgeBio Oncology was a new Marshall Wace position in Q3 2026.
BridgeBio Oncology made up ﹤0.01% of Marshall Wace's portfolio in Q3 2026, its #1819 holding.
44 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q3 2026.

Based on Marshall Wace's 13F filing for Q3 2026, filed 13 Nov 2026.